Biospecimen Contract Research Services Market by Therapeutic Area, Type of Biospecimen, Type of Biospecimen for Non-Oncological Studies, Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2030

Biospecimen Contract Research Services Market by Therapeutic Area, Type of Biospecimen, Type of Biospecimen for Non-Oncological Studies, Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2030

  • August 2021 •
  • 128 pages •
  • Report ID: 6154588 •
  • Format: PDF
INTRODUCTION
Biomedical research is an evolutionary process involving a wide array of research experiments focused on studying diseases and their treatment options; biospecimens are credited as critical components of this process, starting from drug development to clinical trials and epidemiological investigations. Further, in the field of precision medicine, biospecimens act as a link between the biology of a patient and the development of customized therapy. However, procurement and storage of a high quality biospecimen and its analytical evaluation has remained a challenge in the pharmaceutical industry, resulting in delays in research and drug approval timeline. Reliable and efficient traceability of biospecimens demands unique identifiers, advanced data management and quality control systems. Moreover, there are legal and ethical concerns associated with biobanking, and laws and regulations regarding the upkeep of human biospecimens are still evolving.

Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. In fact, new best practices and improved methods of procurement, processing and storage of biospecimens have also been introduced to the industry. The pharmaceutical industry has seen a significant shift towards outsourcing the bioanalytical services to leverage cost-effective methods and overcome the existing capacity constraints. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering biospecimen procurement and analytical services. Based on the prevalent trends, we believe that more developers and innovators are likely to rely on the contract research organizations in order to deal with the existing challenges and drive innovation in drug development, thereby, increasing the opportunities for these service providers in the foreseen future.

SCOPE OF THE REPORT
The “Biospecimen Contract Research Services Market by Therapeutic Area (Oncological Disorders and Other Disorders), Type of Biospecimen for Oncological Studies (FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens), Type of Biospecimen for Non-Oncological Studies (Blood Products, Human Tissue and Other Biospecimens), Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World)): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the companies offering research services related to biospecimens. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
A detailed review of the overall landscape of the companies that claim to offer research services related to biospecimens, including analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of blood products offered (plasma, serum, whole blood, blood cells and bone marrow), types of human tissues offered (Formalin-Fixed Paraffin-Embedded, frozen tissue and fresh tissue), types of biofluids offered (urine, saliva, cerebrospinal fluid, swab, synovial fluid, others), types of other biospecimens offered (fecal matter and nucleic acid), types of analytical services offered (histological analysis, target validation, tissue microarray, tumor tissue analysis and cell based assay), types of samples offered (healthy and diseased samples), types of accreditations received, and geographical reach (North America, Europe, Asia-Pacific and Rest of the World).
A detailed competitiveness analysis of the biospecimen contract research service providers based in different geographies offering services from their own biorepository or through the network of biorepositories, based on portfolio strength (in terms of number of biospecimens, number of analytical services and number of samples offered), service strength (in terms of number of accreditations and geographical reach), supplier strength (in terms of years of experience in this field and company size).
Tabulated profiles of key players offering a wide range of research services for the biospecimens across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographic availability of the services, recent developments and an informed future outlook.
An analysis of partnerships established in this domain since 2015, covering the deals focused on the services related to biospecimens, merger / acqusition, service agreement, service alliance, distribution agreement, joint venture and other agreements.
A case study of the overall landscape of biospecimen procurement service providers (commercial biobanks), based on a number of parameters, such as year of establishment, company size, location of headquarters, types of services offered (sample collection, sample processing, sample logistic / transportation and sample storage), types of biospecimens handled (biofluids, human cells and tissues), therapeutic area (cardiovascular disorders, oncological disorders, neurological disorders, infectious diseases and other therapeutic areas). In addition, it presents a competitiveness analysis of the commercial biobanks based on the availability of their respective biorepositories.
An in-depth analysis of biospecimen contract research service providers, featuring four schematic representations, namely [A] a grid analysis based on the year of establishment and type of analytical services offered, [B] a representation based on the therapeutic area and most active players, [C] an analysis based on the company size and therapeutic area, and [D] a world map representation highlighting the regional distribution of biospecimen research service providers, based on the locations of their biorepositories.

One of the key objectives of the report was to estimate the current market size and the growth opportunities in the biospecimen contract research services market, over the next decade. Based on different parameters, such as overall human biological sample market, share of commercial biobanks and share of biospecimen contract research service providers, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma / Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:
Ramchandra Rao (Managing Director and Business Development Head, BioSpecimen Solutions)
Oleg Granstrem (Director of Business Development, National BioService)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This information is primarily beneficial for us to draw opinions on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been laid on forecasting the market till 2030, the report also provides our independent views on various technological and non-commercial trends emerging in the industry. The opinion is solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources

KEY QUESTIONS ANSWERED
Which are the leading contract researchers offering services related to biospecimens?
Which are the most common types of blood products offered by the biospecimen contract research service providers?
Where are the biorepositories owned by biospecimen contract research service providers located?
Which are the most common type of services offered by the biospecimen contract research service providers?
What type of services is offered by the commercial biobanks?
Which players are offering biospecimen related services through collaborations?
How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the biospecimen contract research services market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to biospecimen and their role in the field of drug discovery. It also features brief description of the factors affecting the quality of biospecimen. In addition, it discusses the regulatory guidelines and outsourcing trends in biospecimen research market. The chapter also discusses the future perspectives of the biospecimen contract research services market.

Chapter 4 provides an overview of overall landscape of the companies that claim to offer research services related to biospecimens, including analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of blood products offered (plasma, serum, whole blood, blood cells and bone marrow), types of human tissues offered (Formalin-Fixed Paraffin-Embedded, frozen tissue and fresh tissue), types of biofluids offered (urine, saliva, cerebrospinal fluid, swab, synovial fluid, others), types of other biospecimens offered (fecal matter and nucleic acid), types of analytical services offered (histological analysis, target validation, tissue microarray, tumor tissue analysis and cell based assay), types of samples offered (healthy and diseased samples), types of accreditations received and geographical reach (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 5 features a detailed competitiveness analysis of the biospecimen contract research service providers based in North America, Europe and Asia-Pacific, which offer services from their own biorepository or through the network of biorepositories. The companies have been segregated into two peer groups based on the availability of biorepository and compared on the basis of portfolio strength (in terms of number of biospecimens, number of analytical services and number of samples offered), service strength (in terms of number of accreditations and geographical reach), supplier strength (in terms of years of experience in this field and company size).

Chapter 6 tabulated profiles of North America based stakeholders offering biospecimen related services. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographical availability of the services, recent developments and an informed future outlook.

Chapter 7 tabulated profiles of Europe and Asia-Pacific based stakeholders offering biospecimen related services. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographical availability of the services, recent developments and an informed future outlook.

Chapter 8 features a detailed analysis of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description of the partnership models (including acquisition / merger, service agreement, service alliance, distribution agreement, joint venture and other agreements) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of partnership, type of partnership, type of collaborator, types of services offered, type of biospecimens offered, therapeutic area, region (where both the parties involved in the collaboration are headquartered) and most active players (in terms of number of partnerships).

Chapter 9 is a case study providing information on close to 20 commercial biobanks which claim to offer the procurement services. It features a detailed analysis based on the year of establishment, company size, location of headquarters, types of services offered (sample collection, sample processing, sample logistic / transportation and sample storage), types of biospecimens handled (biofluids, human cells and tissues), therapeutic area (cardiovascular disorders, oncological disorders, neurological disorders, infectious diseases and other therapeutic areas). In addition, it presents a competitiveness analysis of the commercial biobanks based on the availability of their respective biorepositories.

Chapter 10 presents an in-depth analysis of biospecimen contract research service providers. It featured four schematic representations, namely [A] a grid analysis based on the year of establishment and type of analytical services offered, [B] a representation based on the therapeutic area and most active players, [C] an analysis based on the company size and therapeutic area, and [D] a world map representation highlighting the regional distribution of biospecimen research service providers, based on the locations of their biorepositories.

Chapter 11 presents an insightful market forecast analysis, highlighting the likely growth of the biospecimen contract research services market till the year 2030. In order to provide an informed future outlook, our projections have been segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma / Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World).

Chapter 12 is a summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the biospecimen contract research services market in the future.

Chapter 13 contains the interview transcripts of discussions held with representatives of renowned organizations engaged in the CRISPR technology domain. In this chapter, we have presented the insights on our conversation with Ramchandra Rao (Managing Director and Business Development Head, BioSpecimen Solutions) and Oleg Granstrem (Director of Business Development, National BioService)

Chapter 14 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.